J&J Antipsychotic Paliperidone ER Moves Into Phase III
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug, a metabolite of risperidone formulated using Alza's OROS controlled-release technology, may give the company a successor for its Risperdal franchise. Risperidone loses patent protection in 2007.